FDA Letter API

Westar Nutrition Corp. dba: Viva Life Science, Inc.

Letter data

Company
Westar Nutrition Corp. dba: Viva Life Science, Inc.
Recipient
Westar Nutrition Corp. dba: Viva Life Science, Inc. | United States
Issue date
2018-06-13
Posted date
Not available
FDA office
United States
Subject
Not available
Product
Not available
CMS ID
Not available
Reference number
Not available
FEI
Not available
Inspection dates
Not available

Normalized citations

21 CFR: None found

21 U.S.C.: None found

Related FDA links

No related FDA letter link is present in the source index.

Full source text

CLOSEOUT LETTER Westar Nutrition Corp. dba: Viva Life Science, Inc. June 13, 2018 More Warning Letters Warning Letters About Warning and Close-Out Letters Recipient: Westar Nutrition Corp. dba: Viva Life Science, Inc. United States Issuing Office: United States Office of Human and Animal Foods Division West 5 Los Angeles District Office 19701 Fairchild, Irvine, CA 92612 Telephone: 949-608-4496 UNITED PARCEL SERVICE SIGNATURE REQUIRED June 13, 2018 Emmanuel W. Fan, President/CEO Westar Nutrition Corp. dba Viva Life Science, Inc. 350 Paularino Ave. Costa Mesa, CA 92626 RE: WL #30-15 Close-Out Letter Dear Mr. Fan: The Food and Drug Administration has completed an evaluation of your firm's corrective actions in response to our Warning Letter #30-15, dated July 22, 2015. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. Sincerely, /S/ Sergio Chavez Director Compliance Branch Food and Drug Administration HAF Division West 5 Content current as of: 06/21/2018